Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D03NJY
|
|||
| Former ID |
DCL000228
|
|||
| Drug Name |
SF1126
|
|||
| Synonyms |
CC-1126; SF-1126; L-Serine, N2-(1,4-dioxo-4-((4-(4-oxo-8-phenyl-4H-1-benzopyran-2-yl)morpholinium-4-yl)methoxy)butyl)-L-arginylglycyl-L-alpha-aspartyl-, inner salt
Click to Show/Hide
|
|||
| Drug Type |
Small molecular drug
|
|||
| Indication | Head and neck cancer [ICD-11: 2D42] | Phase 2 | [1] | |
| Hepatocellular carcinoma [ICD-11: 2C12.02; ICD-10: C22.0; ICD-9: 155] | Phase 1 | [1] | ||
| Solid tumour/cancer [ICD-11: 2A00-2F9Z; ICD-10: C00-D48; ICD-9: 140-199, 210-229] | Phase 1 | [2] | ||
| Therapeutic Class |
Anticancer Agents
|
|||
| Company |
Semafore Pharma
|
|||
| Structure |
 |
Download2D MOL
|
||
| Formula |
C39H48N8O14
|
|||
| Canonical SMILES |
C1COCC[N+]1(COC(=O)CCC(=O)NC(CCCN=C(N)N)C(=O)NCC(=O)NC(CC(=O)O)C(=O)NC(CO)C(=O)[O-])C2=CC(=O)C3=C(O2)C(=CC=C3)C4=CC=CC=C4
|
|||
| InChI |
1S/C39H48N8O14/c40-39(41)42-13-5-10-26(36(55)43-20-31(51)45-27(18-33(52)53)37(56)46-28(21-48)38(57)58)44-30(50)11-12-34(54)60-22-47(14-16-59-17-15-47)32-19-29(49)25-9-4-8-24(35(25)61-32)23-6-2-1-3-7-23/h1-4,6-9,19,26-28,48H,5,10-18,20-22H2,(H9-,40,41,42,43,44,45,46,50,51,52,53,55,56,57,58)/t26-,27-,28-/m0/s1
|
|||
| InChIKey |
SVNJBEMPMKWDCO-KCHLEUMXSA-N
|
|||
| PubChem Compound ID | ||||
| PubChem Substance ID | ||||
| SuperDrug ATC ID |
A03AE02
|
|||
| SuperDrug CAS ID |
cas=145158710
|
|||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) | |||
| REF 2 | Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800026065) | |||
| REF 3 | An integrin-targeted, pan-isoform, phosphoinositide-3 kinase inhibitor, SF1126, has activity against multiple myeloma in vivo.Cancer Chemother Pharmacol.2013 Apr;71(4):867-81. | |||
| REF 4 | Pan-PI-3 kinase inhibitor SF1126 shows antitumor and antiangiogenic activity in renal cell carcinoma.Cancer Chemother Pharmacol. 2015 Mar;75(3):595-608. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.